Bristol-Myers Squibb Co (BMY) Position Raised by Ffcm LLC

Ffcm LLC increased its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 5.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 76,646 shares of the biopharmaceutical company’s stock after purchasing an additional 3,966 shares during the quarter. Ffcm LLC’s holdings in Bristol-Myers Squibb were worth $3,984,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Trust Co. of Virginia VA boosted its stake in shares of Bristol-Myers Squibb by 105.7% in the 4th quarter. Trust Co. of Virginia VA now owns 50,048 shares of the biopharmaceutical company’s stock valued at $2,601,000 after purchasing an additional 25,712 shares during the last quarter. Highwater Wealth Management LLC bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $170,000. Yorktown Management & Research Co Inc boosted its stake in shares of Bristol-Myers Squibb by 400.0% in the 3rd quarter. Yorktown Management & Research Co Inc now owns 20,000 shares of the biopharmaceutical company’s stock valued at $1,242,000 after purchasing an additional 16,000 shares during the last quarter. Hollencrest Capital Management boosted its stake in shares of Bristol-Myers Squibb by 176.1% in the 4th quarter. Hollencrest Capital Management now owns 9,604 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 6,126 shares during the last quarter. Finally, Northern Capital Management LLC bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $3,907,000. 73.35% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages have recently issued reports on BMY. ValuEngine raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday, December 7th. Bank of America reduced their target price on shares of Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 19th. Morgan Stanley set a $54.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Thursday, December 20th. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, January 3rd. Finally, Credit Suisse Group reaffirmed a “hold” rating and issued a $59.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, February 15th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $59.40.

Bristol-Myers Squibb stock opened at $49.96 on Friday. Bristol-Myers Squibb Co has a fifty-two week low of $44.30 and a fifty-two week high of $67.44. The company has a market cap of $80.88 billion, a P/E ratio of 12.55, a PEG ratio of 2.22 and a beta of 0.81. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.50 and a current ratio of 1.61.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 48.99%. The business had revenue of $5.97 billion for the quarter, compared to analyst estimates of $5.95 billion. During the same quarter last year, the firm earned $0.68 EPS. Bristol-Myers Squibb’s quarterly revenue was up 9.6% compared to the same quarter last year. Analysts expect that Bristol-Myers Squibb Co will post 4.15 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a yield of 3.28%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is 41.21%.

TRADEMARK VIOLATION NOTICE: “Bristol-Myers Squibb Co (BMY) Position Raised by Ffcm LLC” was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2019/03/17/bristol-myers-squibb-co-bmy-position-raised-by-ffcm-llc.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: What economic reports are most valuable to investors?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply